Oncology investment & partnering trends – today and tomorrow May 9 th , 2019 Sarah E. Hardison, PhD Therapeutic Area Director, Clarivate Analytics Willie T. Reaves, Jr., ACPMPO Director, Partnering Products & Services, Biotechnology Innovation Organization (BIO)
38
Embed
Oncology investment & partnering trends – today and tomorrow · • Oncology captured 42% of deal activity in 2018 • Continuing to see volume and large deals in 2019 • Most
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
Oncology investment & partnering trends – today and tomorrow
May 9th, 2019
Sarah E. Hardison, PhDTherapeutic Area Director, Clarivate Analytics
• Oncology captured 42% of deal activity in 2018• Continuing to see volume and large deals in 2019
• Most deal activity occurs in first and last quarter• Last two quarters have seen a flurry of “mega deals”• What does this mean for the year to come?
Q4 2018-Q1 2019: Setting the pace for the year
from Cortellis 2018 Biopharma Deals & Portfolio Review
4
$-
$500
$1,000
$1,500
$2,000
$2,500
$3,000
$3,500
$4,000
0
50
100
150
200
250
300
350
400
450
500
Drug Technology Company Patent
Mill
ions
Oncology Deals, Q4 2018-Q1 2019
Volume Avg Size
$-
$100
$200
$300
$400
$500
$600
$700
$800
0
20
40
60
80
100
120
140
160
180
Mill
ions
Oncology Drug Deals, Q4 2018-Q1 2019
Volume Avg Size
Oncology deals in the last two quarters
Data from Cortellis Deals Intelligence
5
Oncology drug licensing activity
$-
$100
$200
$300
$400
$500
$600
$700
2013 2014 2015 2016 2017 2018
Mill
ions
Avg Phase II/III Deals
Phase II Phase III
Oncology drug licensing deals, Q4 2018-Q1 2019
● AZ deal with Daiichi Sanyko$6.9B, HER2 ADC
0
10
20
30
40
50
60
70
80
$-
$200
$400
$600
$800
$1,000
$1,200
$1,400
$1,600
Discovery Preclinical Phase 1Clinical
Phase 2Clinical
Phase 3Clinical
Launched
Mill
ions
Oncology Deals by Clinical Phase
Avg Size Volume
Data from Cortellis Deals Intelligence
6
• 3 of the Phase II deals of the last 2Q are >$1B• 2 have an Orphan Drug designation• 50% of the Phase II deals are Orphan Drugs
• 1 Breakthrough, 2 Fast Track
• 12.5% of the Phase III deals are Orphan Drugs• 2 Fast Track
Top Phase II dealsOncology drug licensing deals, Q4 2018-Q1 2019
$- $1,000 $2,000 $3,000 $4,000 $5,000
J&J/YuhanEGFR inhibitor
lazertinib
J&J/arGEN-XCD70 antibodycusatuzumab
GSK/MerckPD-L1/TGFb
bintrafusp alfa
>$1B Phase II Licensing Deals
Upfront Milestone
3From the infographic for the Cortellis Drugs to Watch reportData from Cortellis Deals Intelligence
7
Predicted Success Rates of the top Phase II Deals
Forecasts from Cortellis Analytics: Drug Timeline & Success Rates module
8
Competitive landscape by indicationOncology drug licensing deals, Q4 2018-Q1 2019
NB: some drugs address >1 indication
$1,655
$1,475
$760
$533 $454
$931
$-
$200
$400
$600
$800
$1,000
$1,200
$1,400
$1,600
$1,800
Breast tumor Lung tumor Basal cell cancer Hematologicalmalignancy
Solid tumor Undefined
Mill
ions
Avg Deal Size by Indication
N=1
Data from Cortellis Deals Intelligence
9
Competitive landscape by drug typeOncology drug licensing deals, Q4 2018-Q1 2019
$- $500 $1,000 $1,500 $2,000 $2,500
Monoclonal antibody
Small molecule
Cell therapy
Cancer vaccine
Other biologic
Multispecific antibody
Antibody drug conjugate
Multispecific fusion protein
Millions
Avg Deal Size by Drug Type
Data from Cortellis Deals Intelligence
10
• GSK to license Merck’s bintrafusp alfa: $4.2B• Anti-PD-L1 antibody (avelumab) fused to TGFβR extracellular domain• Currently 16 trials ongoing: Phase I and Phase II (CRC, breast, pancreas, lung)
• LG Chem to license Cue Biopharma’s CUE-101/2 molecules: $1.1B• Recombinant IL-2 fused to peptide/MHC complex• In preclinical testing, $400M in milestones• LG retain right to name next peptide for development
• Amgen to license Molecular Partner’s MP-0310: $547M• DARPin family (designed ankyrin repeats)• Has one FAP and two CD137-binding domains, “bead on a string”• In preclinical testing
Multispecific fusion protein dealsOncology drug licensing deals, Q4 2018-Q1 2019
11
Top 10 licensing deals of the last 2QOncology drug licensing deals, Q4 2018-Q1 2019
$- $2,000 $4,000 $6,000 $8,000
Cue/LG Chem
Yuhan/J&J
SQZ/Roche
arGEN-X/J&J
Tango/Gilead
Agenus/Gilead
Adaptive/Genentech
Abpro/Nanjing CTT
Merck/GSK
Daiichi Sankyo/AstraZeneca
Millions
Top 10 Licensing Deals
Data from Cortellis Deals Intelligence
12
• The top 4 deals in discovery phase are for drug discovery platforms
• $4.0B: Nanjing Chia Tai Tianqing licenses Abpro’s antibody discovery and engineering platforms (multivalent binders)
• $2.3B: Genentech licenses Adaptive Biotechnologies’ TruTCR screening platform to discover TCRs directed against tumor neoantigens
• $1.75B: Gilead licenses Tango Therapeutic’s CRISPR-based target discovery platform with an option on 5 targets
Use Potential Partner’s Profile to EvaluateUse Your Company Profile to Show
The Proof is in the Personalization
• Over ¾ of meeting requests that were accepted & scheduled had targeted subject lines:• Ph2 clinical stage first-in-class anti-
FGFR3 antibody in metastatic bladder cancer
• Interest in your compound AAA-001 in Phase II – In silico clinical trials
• At BIO 2018, over 2/3 of meeting requests that were declined had generic subject lines:• Meeting request• Introduction at BIO• Meet with (company name)• Collaboration
This presentation may contain forward-looking statements regarding Clarivate Analytics. Forward-looking statements provide ClarivateAnalytics’ current expectations or forecasts of future events and may include statements regarding anticipated synergies and other future expectations. These statements involve risks and uncertainties including factors outside of Clarivate Analytics’ control that may cause actual results to differ materially. Clarivate Analytics undertakes no obligation to update or revise the statements made herein, whether as a result of new information, future events or otherwise.